Pasithea Therapeutics Offers Two-pronged Approach in Psychiatric Disease Treatment

Biotechnology

Pasithea Therapeutics, a biotechnology company based in Florida, the United States, has been striving to discover the new and advanced treatments for the neurological and mental disorders along with establishing the psychiatric clinic both in the United States and the United Kingdom for the purpose of offering the services of Ketamine Infusion.

The company said that, its primary focus is now on the discovery side of the drug, along with targeting the new treatments and medicines that have been focusing on the pathophysiology that has been underlying these disorders. Such type of the new treatments is also going to be able to offer the very superior approaches to some of the disorders along with the respect to the tolerability and efficacy of the treatment.

The secondar focus of the company is to establish the clinics in both the United Kingdom and the United States for the purpose of offering the services of ketamine infusion for the treatment of the psychiatric disorders like the treatment of Post Traumatic Stress Disorder (PTSD).

See also  UK MHRA Approved Novavax Covid-19 Vaccine ‘Nuvaxovid’

The ketamine drug is a drug approved by the US FDA and it has also been used as an anesthetic drug for several years. Although, the treatment has recently been repurposed for the treatment of the psychiatric disorders that are being used significantly in lesser doses than all the other forms of the anesthesia, along with the efficacy of the drug.

Swati Jaiswal

Editor/Content Writer